Skip to content
Dx

ICD-10-CM 2027 diagnosis code

C44.1122Basal cell carcinoma of skin of right lower eyelid, including canthus

✓ Billable / specific

C44.1122 is a valid, billable ICD-10-CM code for basal cell carcinoma of skin of right lower eyelid, including canthus. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.Short description: Basal cell carcinoma skin/ right lower eyelid, inc canthus

Code last changed in FY2019 (effective October 1, 2018). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About C44.1122

C44.1122 is the ICD-10-CM diagnosis code for basal cell carcinoma of skin of right lower eyelid, including canthus. It belongs to category C44 (other and unspecified malignant neoplasm of skin), block C43-C44 (melanoma and other malignant neoplasms of skin) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within C44.112 (basal cell carcinoma of skin of right eyelid, including canthus), C44.1122 is specifically for basal cell carcinoma of skin of right lower eyelid, including canthus. Related codes cover upper eyelid, including canthus (C44.1121).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 124 (Other Disorders of the Eye with MCC or Thrombolytic Agent, relative weight 1.2471) and DRG 125 (Other Disorders of the Eye without MCC, relative weight 0.7702), in MDC 02 (Diseases and Disorders of the Eye), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It was added in FY2019, effective October 1, 2018.

Notes that apply from higher levels

Instructions written at a parent level also apply to C44.1122.

› From C44.1 Other and unspecified malignant neoplasm of skin of eyelid, including canthus
Excludes1
  • connective tissue of eyelid (C49.0)
› From C44 Other and unspecified malignant neoplasm of skin
Includes
  • malignant neoplasm of sebaceous glands
  • malignant neoplasm of sweat glands
Excludes1
  • Kaposi's sarcoma of skin (C46.0)
  • malignant melanoma of skin (C43.-)
  • malignant neoplasm of skin of genital organs (C51-C52, C60.-, C63.2)
  • Merkel cell carcinoma (C4A.-)

Broader instructions also apply from Chapter 2: Neoplasms.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2019 (effective 10/1/2018): Added
  • No changes since FY2019.

Common questions about C44.1122

Is C44.1122 billable?

Yes. C44.1122 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can C44.1122 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict C44.1122 as a principal diagnosis.

Is C44.1122 a CC or MCC?

No. C44.1122 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does C44.1122 group to?

C44.1122 is used in the MS-DRG v44.0 logic for MS-DRG 124 (Other Disorders of the Eye with MCC or Thrombolytic Agent) and MS-DRG 125 (Other Disorders of the Eye without MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.